Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naïve Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy

Am J Hematol. 2026 Mar;101(3):570-576. doi: 10.1002/ajh.70203. Epub 2026 Jan 8.

Abstract

Real-world experience using momelotinib as first-line JAK2 inhibitor therapy in myelofibrosis. Anemia response was moderate (23%) while treatment-emergent adverse events included nephropathy (29%) and peripheral neuropathy (20%).

Keywords: SH2B3; fedratinib; pacritinib; ruxolitinib; side effects.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Anemia* / chemically induced
  • Anemia* / drug therapy
  • Benzamides* / administration & dosage
  • Benzamides* / adverse effects
  • Benzamides* / therapeutic use
  • Drug Approval
  • Female
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors
  • Janus Kinase Inhibitors* / adverse effects
  • Janus Kinase Inhibitors* / therapeutic use
  • Kidney Diseases* / chemically induced
  • Male
  • Middle Aged
  • Nitriles
  • Peripheral Nervous System Diseases* / chemically induced
  • Primary Myelofibrosis* / complications
  • Primary Myelofibrosis* / drug therapy
  • Protein Kinase Inhibitors* / adverse effects
  • Protein Kinase Inhibitors* / therapeutic use
  • Pyrimidines* / administration & dosage
  • Pyrimidines* / adverse effects
  • Pyrimidines* / therapeutic use
  • Pyrrolidines* / adverse effects
  • Pyrrolidines* / therapeutic use
  • Sulfonamides* / adverse effects
  • Sulfonamides* / therapeutic use
  • United States

Substances

  • Pyrimidines
  • Janus Kinase 2
  • Benzamides
  • JAK2 protein, human
  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
  • Janus Kinase Inhibitors
  • Pyrrolidines
  • Sulfonamides
  • Protein Kinase Inhibitors
  • Nitriles